ArticleAntioxidants (Basel, Switzerland)2026
A Pyrazole-Based Small Molecule, KB3409, Restores Mitochondrial Function via VCP Activation and RCN2-Dependent Ca
Article in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Cellular senescence is characterized by the accumulation of reactive oxygen species (ROS), and the selective elimination of excessive ROS remains a key therapeutic challenge. Through antioxidant screening, we identified the pyrazole-based small molecule KB3409 as a potent regulator that reduces ROS levels in senescent fibroblasts. To elucidate its mechanism of action, we performed target identification and found that KB3409 directly binds to valosin-containing protein (VCP) and reticulocalbin-2 (RCN2). Functionally, KB3409 acts as an allosteric activator of VCP, enhancing its ATPase activity and promoting autophagic flux. This activation facilitates the selective clearance of dysfunctional mitochondria, thereby improving mitochondrial quality control and limiting ROS generation at its source. Concurrently, KB3409 modulates RCN2-dependent Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.